MCID: FNC003
MIFTS: 18

Functionless Pituitary Adenoma

Categories: Cancer diseases, Endocrine diseases

Aliases & Classifications for Functionless Pituitary Adenoma

MalaCards integrated aliases for Functionless Pituitary Adenoma:

Name: Functionless Pituitary Adenoma 12
Non-Secretory Adenoma of the Pituitary Gland 12
Non-Functioning Neoplasm of the Pituitary 12
Non-Functioning Pituitary Gland Neoplasm 73

Classifications:



External Ids:

Disease Ontology 12 DOID:5715
NCIt 50 C4009 C4348
UMLS 73 C0338078

Summaries for Functionless Pituitary Adenoma

MalaCards based summary : Functionless Pituitary Adenoma, also known as non-secretory adenoma of the pituitary gland, is related to pituitary adenoma and esophagus squamous cell carcinoma. An important gene associated with Functionless Pituitary Adenoma is MEG3 (Maternally Expressed 3), and among its related pathways/superpathways is LncRNA-mediated mechanisms of therapeutic resistance. The drugs Cabergoline and Dopamine have been mentioned in the context of this disorder. Affiliated tissues include pituitary, lung and kidney.

Related Diseases for Functionless Pituitary Adenoma

Graphical network of the top 20 diseases related to Functionless Pituitary Adenoma:



Diseases related to Functionless Pituitary Adenoma

Symptoms & Phenotypes for Functionless Pituitary Adenoma

Drugs & Therapeutics for Functionless Pituitary Adenoma

Drugs for Functionless Pituitary Adenoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 41)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Cabergoline Approved Phase 3,Phase 2,Not Applicable 81409-90-7 54746
2
Dopamine Approved Phase 3,Phase 2,Not Applicable 51-61-6, 62-31-7 681
3
Somatostatin Approved, Investigational Phase 2, Phase 3,Phase 1 51110-01-1, 38916-34-6 53481605
4
Pasireotide Approved Phase 2, Phase 3 396091-73-9 9941444
5
Octreotide Approved, Investigational Phase 3,Phase 1 83150-76-9 383414 6400441
6 Hormones Phase 2, Phase 3,Phase 1,Not Applicable
7 Dopamine Agents Phase 3,Phase 2,Not Applicable
8 Antiparkinson Agents Phase 3,Phase 2
9 Dopamine agonists Phase 3,Phase 2,Not Applicable
10 Neurotransmitter Agents Phase 3,Phase 2,Not Applicable
11 Sympathomimetics Phase 2, Phase 3,Phase 3,Not Applicable
12 Hormone Antagonists Phase 2, Phase 3
13 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 2, Phase 3
14 Autonomic Agents Phase 2, Phase 3,Phase 3,Not Applicable
15 Peripheral Nervous System Agents Phase 2, Phase 3,Phase 3,Not Applicable
16 Cardiotonic Agents Phase 2, Phase 3,Phase 3,Not Applicable
17 Protective Agents Phase 2, Phase 3,Phase 3,Not Applicable
18 Radiopharmaceuticals Phase 3,Phase 1
19 Antineoplastic Agents, Hormonal Phase 3,Phase 1
20 Gastrointestinal Agents Phase 3,Phase 1
21 Edotreotide Phase 3,Phase 1
22
Rosiglitazone Approved, Investigational Phase 2 122320-73-4 77999
23
Maleic acid Experimental Phase 2 110-16-7 444266
24 Adrenocorticotropic Hormone Phase 2
25 Hypoglycemic Agents Phase 2
26 Pancreatic Polypeptide Investigational Phase 1 59763-91-6
27
Propofol Approved, Investigational, Vet_approved 2078-54-8 4943
28
Bromocriptine Approved, Investigational Not Applicable 25614-03-3 31101
29 Calcium, Dietary
30 Anesthetics, General
31 Hypnotics and Sedatives
32 Anesthetics, Intravenous
33 Central Nervous System Depressants
34 Anesthetics
35 Vasoconstrictor Agents
36 Arginine Vasopressin
37 arginine
38 Coagulants
39 Natriuretic Agents
40 Hemostatics
41 Vasopressins

Interventional clinical trials:

(show all 20)
# Name Status NCT ID Phase Drugs
1 Cabergoline in Nonfunctioning Pituitary Adenomas Completed NCT03271918 Phase 3 Cabergoline
2 Response to Cabergoline and Pasireotide in Non-functioning Pituitary Adenomas and Resistant Prolactinomas Completed NCT01620138 Phase 2, Phase 3 Pasireotide;cabergoline
3 Dopamine Agonist Treatment of Non-functioning Pituitary Adenomas Recruiting NCT02288962 Phase 3 cabergoline
4 Ga-68-DOTATOC -PET in the Management of Pituitary Tumours Recruiting NCT02419664 Phase 3
5 Evaluate the Efficacy and Safety of Pasireotide LAR on the Treatment of Patients With Clinically Non-Functioning Pituitary Adenoma. Completed NCT01283542 Phase 2 Pasireotide LAR
6 Pasireotide LAR Therapy of Silent Corticotroph Pituitary Tumors Recruiting NCT02749227 Phase 2 Pasireotide LAR
7 Rosiglitazone in Treating Patients With Pituitary Tumors Terminated NCT00616642 Phase 2 rosiglitazone maleate
8 Exploratory Study of Farletuzumab to Treat Resectable, Non-functioning Pituitary Adenomas Withdrawn NCT01203618 Phase 2 Farletuzumab
9 Temozolomide in Treating Patients With Invasive Pituitary Tumors Withdrawn NCT00601289 Phase 2 temozolomide
10 Antineoplaston Therapy in Treating Patients With Neuroendocrine Tumor That Is Metastatic or Unlikely to Respond to Surgery or Radiation Therapy Withdrawn NCT00003514 Phase 2 antineoplaston A10;antineoplaston AS2-1
11 Yttrium Y 90 SMT 487 in Treating Patients With Refractory or Recurrent Cancer Completed NCT00006368 Phase 1
12 Prospective Study of Clinically Nonfunctioning Pituitary Adenomas Unknown status NCT01556230
13 Characterization of Receptors in Non-functioning Pituitary Macroadenomas Unknown status NCT00852501
14 Calcium Homeostasis in Acromegaly: Effect of Surgical/Medical Treatment and Comparison With Nonfunctioning Pituitary Tumors Completed NCT01568359
15 Predictive Factors of Recurrence of Non Functioning Pituitary Adenomas : a Retrospective Study of 220 Patients in the Reims University Hospital, France Completed NCT02803697
16 Acute Side Effects in Patients Who Are Undergoing Stereotactic Radiosurgery for Brain Tumors or Other Brain Disorders Completed NCT00255671
17 Comparison of Propofol Requirement Between Patients With Pituitary Somatotroph Tumor and With Nonfunctioning Pituitary Tumor in Transsphenoidal Pituitary Surgery Under Total Intravenous Anesthesia Recruiting NCT03465423
18 Seoul National University Pituitary Disease Cohort Study Recruiting NCT03474601
19 Transsphenoidal Extent of Resection Study Active, not recruiting NCT02357498 Not Applicable
20 Dopamine D2 Receptors(D2R) Imaging in Nonfunctioning Pituitary Adenoma(NFPA) Not yet recruiting NCT03714763 Not Applicable Drug treatment

Search NIH Clinical Center for Functionless Pituitary Adenoma

Genetic Tests for Functionless Pituitary Adenoma

Anatomical Context for Functionless Pituitary Adenoma

MalaCards organs/tissues related to Functionless Pituitary Adenoma:

41
Pituitary, Lung, Kidney, Liver, Bone, Thyroid, Myeloid

Publications for Functionless Pituitary Adenoma

Variations for Functionless Pituitary Adenoma

Expression for Functionless Pituitary Adenoma

Search GEO for disease gene expression data for Functionless Pituitary Adenoma.

Pathways for Functionless Pituitary Adenoma

Pathways related to Functionless Pituitary Adenoma according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1 9.7 HOTAIR MEG3

GO Terms for Functionless Pituitary Adenoma

Sources for Functionless Pituitary Adenoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....